Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Summary

Kamada Ltd. reported record-high financial results for H1 2026 with double-digit profitable growth and affirmed its 2026 annual guidance. The company achieved its strongest financial performance in its history as a global biopharmaceutical leader in specialty plasma-derived therapies.